TipRanks
Oppenheimer: these 3 shares can increase more than 80%
Wall Street’s best businesses look not only at the stocks, but also at the big picture. And Oppenheimer’s chief investment strategist, John Stoltzfus, is particularly adept at showing us the macro view. In its first note of the new year, Stoltzfus notes a series of factors that will affect the markets. The big news, of course, the 800-pound gorilla that cannot be ignored is the ongoing COVID epidemic. The disease is returning strongly now that we are far into the winter – which is somewhat expected, as it is typical of flu-like respiratory viruses. With the winter virus boom, we also have to contend with a new round of lock-in policies, instituted at the state or local level. It is hoped that the newly available COVID vaccines will put a damper on the new coronavirus by spring. leads to less resistance to vaccination against Covid-19 than many experts feared early in the pandemic. We expect the stock markets to remain sensitive to the developments linked to the pandemic that has been holding the US and the world economy hostage for almost a year, “According to Stoltzfus, the election in Georgia is the second biggest news, but according to Stoltzfus probably the impression on the market.Both Democratic candidates won Senate seats, giving the incoming Biden administration the ability to push through Congress policy on any opposition – at least for the next two years. Control of one of the presidency and Congress’s worries Stoltzfus In his campaign, Joe Biden promised to reverse Trump’s tax policy and launch a series of major spending initiatives. likely to increase both taxes and federal spending.And according to Stoltzfus, it will probably cost the markets; Stoltzfus believes that embarrassing progressive / democratic policies will leave the S&P 500 vulnerable to losses of between 6% and 10%. Before moving on to selling positions, Oppenheimer’s equity analysts remind investors that compelling opportunities can still be found. The firm’s analysts have highlighted three stocks that they say are expected to rise 80% for the coming year. Using TipRanks’ database, we were told that the rest of the street agrees, as all three boast a consensus from a Strong Buy analyst. miRagen Therapeutics (MGEN) miRagen Therapeutics aims to develop new treatment options for diseases that today’s therapy cannot adequately improve. The company’s flagship drug candidate is VRDN-001, a monoclonal anti-IGF-1R antibody in clinical stages as a treatment for thyroid eye disease (TED). miRagen acquired the rights to VRDN-001 at the end of last year following the acquisition of Veridian Therapeutics in October. The monoclonal antibody is about to enter Phase 2 clinical trials, with the initial results expected around mid-2021. miRagen funded its current research with a $ 91 million capital increase, arranged in a private placement funding agreement. With the agreement, miRagen ended the third quarter with $ 144 million in cash on hand, but more importantly, a clear cash career that extends to 2023. Among the bulls is Oppenheimer analyst Leland Gershell, who rates MGEN as a better performer (ie buy ), along with a price target of $ 37. This figure indicates room for 102% growth in one year. (To view Gershell’s record, click here. Gershell supports his position, saying: ‘Recent acquisition of Viridian and $ 91 million raises miRagen at a new rate as incoming programs position it to compete in the fertile market for thyroid eye diseases … we see generous income potential for [VRDN-001], and its higher potential can enable differentiation … We expect that progress in the development of MGEN’s TED candidates will support better performance. In general, Wall Street likes the risk / reward factor that plays out here, as TipRanks shows a strong buying consensus rooted in the success of MGEN. Shares sell for $ 18.26 and have an average price target of $ 32. This target implies an increase of 75% from current levels. (See MGEN stock analysis on TipRanks) Oric Pharmaceuticals (ORIC) The success of the pharmacological industry has ironically posed a major challenge: many diseases are becoming resistant to existing treatments. Many cancers are one of the diseases that are subject to resistance and consequent relapse, serious problems that affect the quality of life of the patient and increase the mortality rate. Oric Pharmaceuticals, a research firm for biopharma in clinical conditions, is working on treatments to overcome cancer resistance. ORIC’s main candidate is ORIC-101, which shows promise as an antagonist to glucocorticoid (GR) receptors. The drug is undergoing two separate phase 1b trials, one for prostate cancer and one for solid tumors. Modern medicine research is expensive and Oric recently raised capital through a successful public offering of shares. The company put more than 5.79 million new shares on the market in November, at $ 23 each, and had a return of more than $ 133.3 million. Kevin DeGeeter, an analyst at Oppenheimer, is 5 star. DeGeeter supports its Outperform (ie Buy) rating with a price target of $ 62, which implies an upward potential of one year of 88%. (To view the performance history of DeGeeter, click here) In support of his optimistic stance, DeGeeter writes: ‘We view ORIC as an investment in a leadership team with an earlier history to successfully develop clinically important cancer medicine. Our thesis assumes … clinical data that best support the class profile of ORIC-101, based on ease of use or outstanding efficacy in the biomarker-selected population. We believe that current investor expectations add significant value to potential best-in-class ORIC-101 profile and management skills. Overall, ORIC equities receive a unanimous inch from the analyst’s consensus, with three recent Buy reviews having a strong Buy rating. The stock price is $ 32.91, while the average price target of $ 50.67 indicates room for a growth of ~ 54%. (See ORIC stock analysis on TipRanks) Triterras (TRIT) Next up is a unicorn, a billion-dollar fintech startup that has been on the public market for less than three months. Triterras offers an online trading and trading finance platform, Kratos, based on blockchain technology. Trade finance, or the provision of credit services in the physical transportation of market products, is estimated to be worth $ 40 billion annually; Triterras’ platform uses the secure nature of blockchain as a selling point for online merchants. Triterras was announced by a SPAC merger. a business combination with a specialty sourcing business. These companies exist to acquire a target company, inject capital and then place the joint entity on the public markets. Analyst Owen Lau likes his view on this stock for Oppenheimer. From the current status of the company, he writes, “… results and momentum seem strong, and the full annual guidance implies a growth of 235% and 142% in turnover and net income from a low base. More importantly, while the company is growing faster than other high-growth markets, the stock is trading at a discount to low-end markets on average. ‘At last point, Lau’s a bump, saying:’ We’re seeing an interesting paper-to-electronics opportunity in Triterras, which uses blockchain technology to take the low-tech adoption into the trade and finance industry. disrupt. Consistent with these remarks, Lau TRIT rates better (ie buy), and its $ 23 price target implies a 93% growth for the year ahead. (To view Lau’s record here, click here.) Overall, this company has three recent reviews on record, and these are all for sale, which makes the strong buy analyst unanimously positive. Shares are priced at $ 10.94 with an average price target of $ 19, giving the stock ~ 60% upside potential for one year. (See TRIT stock analysis at TipRanks) Visit TipRanks ‘best-selling stocks, a newly launched tool that combines all of TipRanks’ equity insights. those of the popular analysts. The content is for informational purposes only. It is very important to do your own analysis before investing.